镭-223治疗去势抵抗性前列腺癌骨转移的研究进展  

Research Progress of 223-Ra in the Treatment of Bone Metastases from Desmoplasia-resistant Prostate Cancer

作　　者：卢畅 张冉[1] 张丽 丁佳欣 孙悦[1] 冉卓灵 郑雨璇 喻琳 高旭 谢晶 周焕 宫建[1] LU Chang;ZHANG Ran;ZHANG Li;DING Jiaxin;SUN Yue;RAN Zhuoling;ZHENG Yuxuan;YU Lin;GAO Xu;XIE Jing;ZHOU Huan;GONG Jian(Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation,Shenyang Pharmaceutical University,Shenyang 110016,China;Clinical Trial Research Center,the First Affiliated Hospital of Bengbu Medical University,Bengbu 233000,China)

机构地区：[1]沈阳药科大学药物流行病与临床药物评价课题组,沈阳110016 [2]蚌埠医科大学第一附属医院临床试验研究中心,蚌埠233000

出　　处：《医药导报》2025年第3期446-451,共6页Herald of Medicine

基　　金：沈阳药科大学中青年教师事业发展支持计划立项(ZQN202205)。

摘　　要：前列腺癌是最常见的男性泌尿系统恶性肿瘤之一,去势抵抗性前列腺癌骨转移是疾病进展的重要阶段,严重影响患者生活质量及生存期。近年来,随着核素治疗技术的发展,镭-223(223-Ra)作为一种新型α靶向疗法,对去势抵抗性前列腺癌骨转移具有良好疗效。该文综述223-Ra特点、作用机制及其治疗去势抵抗性前列腺癌骨转移的主要研究成果,以期为223-Ra在去势抵抗性前列腺癌骨转移的临床应用提供参考。Prostate cancer is one of the most common male urological malignancies,in which bone metastasis of desmoplasia-resistant prostate cancer is an important stage in the progression of the disease,which seriously affects the quality of life and survival of patients.With the development of nuclide therapy technology in recent years,223-Ra,as a new type of alpha-targeted therapy,has shown good efficacy in the treatment of desmoplasia-resistant prostate cancer bone metastasis.The purpose of this paper is to review the characteristics,mechanism of action,treatment,and the main research results of its treatment of desmoplasia-resistant prostate cancer bone metastasis,and provide a comprehensive review of the clinical application of 223-Ra in the treatment of desmoplasia-resistant prostate cancer bone metastasis for the clinical application of 223-Ra in prostate cancer bone metastasis.

关 键 词：镭-223 放射性核素 去势抵抗性前列腺癌 

分 类 号：R979.1[医药卫生—药品] R737[医药卫生—药学]